A Safety Study of LY3526318 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

April 21, 2021

Study Completion Date

April 21, 2021

Conditions

Healthy

Interventions

DRUG

LY3526318

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

PRA Health Sciences, Groningen

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04682119 - A Safety Study of LY3526318 in Healthy Participants | Biotech Hunter | Biotech Hunter